Bio-Techne/$TECH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Ticker
$TECH
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
3,100
ISIN
US09073M1045
Website
Bio-Techne Metrics
BasicAdvanced
$8.4B
64.21
$0.83
1.46
$0.32
0.60%
Price and volume
Market cap
$8.4B
Beta
1.46
52-week high
$83.62
52-week low
$46.01
Average daily volume
2M
Dividend rate
$0.32
Financial strength
Current ratio
3.707
Quick ratio
2.233
Long term debt to equity
20.29
Total debt to equity
20.986
Dividend payout ratio (TTM)
38.45%
Interest coverage (TTM)
13.77%
Profitability
EBITDA (TTM)
280.897
Gross margin (TTM)
66.32%
Net profit margin (TTM)
10.89%
Operating margin (TTM)
18.59%
Effective tax rate (TTM)
19.21%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
5.05%
Return on equity (TTM)
6.53%
Valuation
Price to earnings (TTM)
64.206
Price to revenue (TTM)
6.968
Price to book
4.16
Price to tangible book (TTM)
13.79
Price to free cash flow (TTM)
38.154
Free cash flow yield (TTM)
2.62%
Free cash flow per share (TTM)
139.67%
Dividend yield (TTM)
0.60%
Forward dividend yield
0.60%
Growth
Revenue change (TTM)
4.72%
Earnings per share change (TTM)
-34.18%
3-year revenue growth (CAGR)
3.94%
10-year revenue growth (CAGR)
10.98%
3-year earnings per share growth (CAGR)
-15.44%
10-year earnings per share growth (CAGR)
1.29%
10-year dividend per share growth (CAGR)
0.08%
What the Analysts think about Bio-Techne
Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.
Bulls say / Bears say
Bio-Techne delivered strong organic revenue growth with a 9% increase in Q2 and 6% in Q3 driven by robust demand in its Protein Sciences and Diagnostics & Spatial Biology segments.
Adjusted operating margin expanded to 34.9% in Q3 from 33.0% a year earlier, reflecting successful profitability initiatives and operational leverage.
Institutional investors are increasing stakes, with Price T. Rowe Associates boosting its holdings by 13.1% to 10.65 million shares in Q4 2024, underscoring confidence in Bio-Techne’s long-term prospects
Bio-Techne’s share price has fallen 38.5% from its 52-week high and declined 2.28% on July 15, marking three straight days of losses and signaling waning investor confidence.
Third quarter GAAP EPS dropped to $0.14 from $0.31 year-over-year, exposing volatility in core earnings and raising concerns about near-term profitability.
Citigroup cut its price target on Bio-Techne from $80 to $70 and R.W. Baird downgraded the rating to ‘hold’, highlighting analyst skepticism about the firm’s growth trajectory
Data summarised monthly by Lightyear AI. Last updated on 16 Jul 2025.
Bio-Techne Financial Performance
Revenues and expenses
Bio-Techne Earnings Performance
Company profitability
Bio-Techne News
AllArticlesVideos
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
Business Wire·3 days ago
Bio-Techne exceeds profit expectations, announces new share buyback plan
Reuters·2 months ago
U.S. politician makes suspicious biotech stock bet
Finbold·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Techne stock?
Bio-Techne (TECH) has a market cap of $8.4B as of July 18, 2025.
What is the P/E ratio for Bio-Techne stock?
The price to earnings (P/E) ratio for Bio-Techne (TECH) stock is 64.21 as of July 18, 2025.
Does Bio-Techne stock pay dividends?
Yes, the Bio-Techne (TECH) stock pays dividends to shareholders. As of July 18, 2025, the dividend rate is $0.32 and the yield is 0.6%. Bio-Techne has a payout ratio of 38.45% on a trailing twelve-month basis.
When is the next Bio-Techne dividend payment date?
The next Bio-Techne (TECH) dividend payment date is unconfirmed.
What is the beta indicator for Bio-Techne?
Bio-Techne (TECH) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.